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ABSTRACT 
To date, the therapeutic efficacy of human mesenchymal stem cells (hMSCs) has been investigated in 
various clinical trials with moderate or in some cases inconsistent results. The still elusive reproducibility relates 
in part with constitutive differences in the cell pUHSDUDWLRQWUDQVODWHGLQWRYDULDEOH³FHOOSRWHQFies´2WKHUIDFWRUV
include poor cell homing and survival, and age/disease-associated host tissue impairment. It is well accepted 
that within in vivo niches MSCs exist as heterogeneous cell populations with different stemness propensities and 
supportive functions. Phenotype-based MSC purification of homogeneous subsets can result in cell populations 
with distinct biological functions. In addition, preclinical studies have shown that MSC functionalization in vitro, 
via cell priming, can boost their immunomodulatory, trophic and reparative capacities in vivo. Therefore, in the 
present review we discuss how phenotype-based MSC purification and MSC priming technologies can contribute 
to an improved MSC-based product for safer and more effective therapeutic applications.      
IMPACT:  
Culture expansion of MSC has detrimental effects on various cell characteristics and attributes (e.g., 
phenotypic changes and senescence), which, in addition to inherent inter-donor variability negatively impact the 
standardization and reproducibility of their therapeutic potential. The identification of innate distinct functional 
MSC subpopulations, as well as the description of ex vivo protocols aimed at maintaining phenotypes and 
enhancing specific functions have the potential to overcome these limitations. The incorporation of those 
approaches into cell-based therapy would significantly impact the field, as more reproducible clinical outcomes 
may be achieved. 
 
INTRODUCTION 
Safety and efficacy of human mesenchymal stem cells (MSCs)-based therapies are being investigated 
in a growing number of clinical trials for various disorders including musculoskeletal, cardiovascular, 
autoimmune, neurodegenerative and gastrointestinal (http://clinicaltrials.gov). Initial results from many of such 
studies reveal that these therapies show a significant degree of variability with cases of non-reproducible clinical 
data. The inconsistent evidence potentially relates to intrinsic differences in the cell-based products used, 
including lack of standardized features in the preparations UHIOHFWHG LQ³potency´GLVFUHSDQFLHV, as well as to 
factors related with the therapy itself (e.g., cell homing to target tissues and subsequent survival), and the host 
receiving the therapy (e.g., age and disease-associated conditions).  
 Active research is being conducted to help minimize the reported variability, ultimately aiming at 
increasing clinical reproducibility. Efforts include thorough characterization of cell preparations including the 
description of constitutive variations (i.e., cell heterogeneity), and methods to stimulate MSCs with chemical and 
physical conditions to induce and/or to modulate specific attributes of the cells (i.e., cell priming). In this review, 
we collect and discuss available evidence of such efforts, focusing on two main aspects: the identification of 
specific subsets/subpopulations of MSCs from different sources (heterogeneity), and the derivation of stimulatory 
protocols applied to the cells a priori to modulate cellular phenotypes and homing capacity (priming).  
1. MSC SUBSETS/SUBPOPULATIONS 
The fact that standard MSC cultures consist of functionally heterogeneous cell subsets is well recognized 
in the literature, however, the reasons for such heterogeneity are poorly understood. In our opinion, such 
heterogeneity arises from two different factors: firstly, from an inherent heterogeneity of culture-initiating MSCs, 
and second, from culture-induced accumulation of senescent cells, which in later passages become predominant 
DQGWKHUHIRUHVLJQLILFDQWO\LPSDFWRQFXOWXUHV¶SRWHQF\$VWKHODWWHUSKenomenon has been reviewed extensively 
(1, 2), this section will focus on tissue-inherent MSC heterogeneity, which is closely linked to their local niches 
and tissue topography. 
It is widely accepted that MSC populations within the different niches and tissues are highly 
heterogeneous; purification of homogeneous subsets with distinct biological functions is a challenge. However, 
isolated MSCs are generally analyzed for their clonogenic potential by the CFU-F assay and only limited 
information exists about markers that discriminate between developmentally, functionally and morphologically 
distinct MSC subsets (3). In here, we summarize recent studies aimed to identify different MSC subsets in the 
bone marrow (BM) as well as adipose and synovial tissues. 
1.1  Bone marrow MSCs 
Location markers: CD146 and CD271. 
Bone marrow contains stem and progenitor cells for both hematopoietic and non-hematopoietic lineages. 
Bone marrow MSCs (referred also as multipotent stromal cells and skeletal stem cells - SSCs) reside in the 
postnatal BM cavities and give rise to bone, cartilage, marrow-fat and hematopoiesis-supportive stroma following 
a specific sequence of events during postnatal development (4-6). A pioneering work by Tormin et al has clearly 
demonstrated that human BM MSCs were present in two different regions within the BM cavities: in the 
perivascular niche, where they were characterized by CD146 marker expression, and in the bone-lining location, 
where MSC lacked this marker (7). Both, CD146+ and CD146Neg MSC subpopulations were CD271+ and had 
similar clonogenic capacities and gene expression profiles characterized by the simultaneous expression of 
multiple-lineage transcripts. Therefore, while CD271+CD146Neg cells are present in bone surfaces, 
CD271+CD146+ MSCs constitute the bona fide perivascular component of the BM (Figure 1). Furthermore, 
adherent cultures derived from these two subpopulations had similar differentiation capacities in vitro and in vivo. 
In a more recent study Espagnolle et al have expanded BM MSCs at the clonal level and showed the presence 
of CD146 high and CD146 Neg/low clones (8). In agreement with Tormin et al study (7), they found no differences in 
the tri-lineage as well as hematopoietic support potentials between these two types of clones, however clonal 
cultures derived from the CD146high subset had slightly slower growth rates and a more pronounced vascular 
smooth muscle phenotype, which was tested using functional cell contraction assay in a collagen gel. These 
findings supported Tormin et al study (7) in which BM CD146+ cells were shown to have a topography of 
pericytes. The significance of CD146 expression on these perivascular MSCs remains to be investigated. In 
regards to CD146 expression on BM MSCs, it is interesting to mention that Maijenburg et al have also found 
CFU-Fs in the CD271NegCD146+ subset of fetal BM (9). CD146 expression was shown to be dependent on 
calcium (10) and oxygen levels (7) and can therefore reflect the niche environment in which this specific BM 
MSC subset resides. Less information is so far available with respect to CD146Neg BM MSCs. Because significant 
reduction of CD271+CD146+ population was found in elderly adults, compared with children (9), it is possible that 
CD146Neg FHOOVUHSUHVHQWDVXEVHWRIµDJHG¶%006&V, however, this is not consistent with Tormin et al data (7) 
that showed no differences in the clonogenicity between CD271+CD146+ and CD271+CD146Neg subpopulations.  
The perivascular localization concept of BM MSCs has been recently reinforced by Lin et al. pioneering 
study, showing that intra-arterially injected BM MSCs can serially engraft from the circulation into irradiated BM 
and proliferate in vivo, retaking the perivascular space around BM vessels and sinusoids (11). Recent reports  
(12, 13) expanded the notion of MSC subpopulations beyond the CD146 and CD271 discrimination reported in 
human BM, incorporating additional markers thus far identified in mouse studies. For instance, the perivascular 
BM MSCs can be further divided into two main categories according to the blood vessel they associate with: the 
periarteriolar MSCs (Nestinbright, NG2+Į60$+, CD271+, CD146+), and the perisinusoidal MSCs (Nestindim, leptin 
receptor (LepR)+, CD271+, CD146+). These subpopulations have distinct functions as they support 
hematopoiesis and probably are related with local homeostatic responses. Along those lines, Mendez-Ferrer et 
al. showed that Nestin+ MSCs contain all BM colony-forming-unit fibroblastic activity, are spatially associated 
with hematopoietic stem cells (HSCs) and highly express HSC maintenance and retention genes such as those 
encoding the cytokines chemokine (C-X-C motif) ligand 12 (CXCL12) and stem cell factor (SCF) (14, 15). These 
perivascular cells known as CXCL12-abundant reticular (CAR) cells express Nestin, LepR, myxovirus 
resistance-1 (Mx-1), the transcription factor paired related homeobox-1 (Prx-1) that characterize cells of limb bud 
mesoderm, and transcription factor osterix (OSX or SP7) that regulates osteoblast maturation (13). Importantly, 
Sachetti et al. suggested that CD146+ human MSCs may be the in vitro counterpart of CAR cells as they acquire 
the same phenotype in in vivo transplantation models reconstituting the hematopoietic environment (16). 
Therefore, except CD146+ 06&V¶DELOLW\WRUHFRQVWLWXWHERQHDQG%0VWURPDDIWHURUWKRWRSLFDQGKHWHURWRSLF
transplantation models, they have an important role in HSC niche maintenance. To further support this notion, 
Corselli et al. showed that CD146+CD34NegCD45Neg SHULYDVFXODUFHOOVVXSSRUWWKH+6&V¶VWHPQHVVWKURXJKFHOO-
to-FHOO FRQWDFW DQG 1RWFK VLJQDOLQJ DFWLYDWLRQ DQG +6&V¶ DELOLW\ WR HQJUDIW WR SULPDU\ DQG VHFRQGDU\
immunodeficient mice. In contrast, unfractionated and CD146Neg MSCs induce differentiation and inhibit ex vivo 
+6&V¶PDLQWHQDQFH(17).  
In summary, the combined literature to date indicates that within human BM stroma, the CD146+ 
subpopulation has a preferential perivascular topography and hematopoietic support function, whereas CD271 
is expressed on both perivascular and bone lining MSCs; precise functions of these molecules on BM MSCs 
remain to be investigated. 
Other markers:  
In recent years, a number of novel markers to identify distinct MSC subsets within the CD271+ fraction in 
human BM were proposed, including CD140b (18), MSCA-1 (19, 20), CD90 and CD106 (21), CD140a (22) and 
SUSD2 (20); however their expression in situ has not been performed therefore the precise tissue locations of 
these putative subsets remain unknown. Another surface marker of interest is CD56. Early studies have shown 
that CD56 molecule was highly-specific for bone-lining cells (23), in the same location of CD271+CD146Neg MSC 
subset in the Tormin et al study (7) (Figure 1); however CD56 has not as yet been used to isolate BM MSCs as 
a single marker or in combiQDWLRQZLWK&'$Q LQWHUHVWLQJVWXG\IURP%XKULQJ¶V ODERUDWRU\ (19) showed a 
distinct morphology and potential chondrogenic bias of the CD271+MSCA-1+CD56+ BM MSC subset. These 
findings are awaiting an independent confirmation, but were confirmed in part by Cuthbert et al who found MSCA-
1 expression in the CD45NegCD271+ fraction of BM aspirates (24). Busser et al also found better chondrogenic 
potential of MSCA-1+ selected MSCs than unselected ones and higher chondrogenic capacity from BM MSCs 
grown from the CD271+ fraction (20). Contrary, Jezierska et al found better chondrogenesis of cultures expanded 
from CD271Neg rather than CD271+ cells, after differentiation on gelated collagen microspheres (25).  
CD271 marker is lost during culture expansion, therefore other markers were studied to discover MSC 
subpopulations present in both in fresh and early-passage expanded cells. When Qian et al tested CD44 as one 
of those markers, they found that CD44 was absent in freshly isolated BM MSC population because the cells 
that co-expressed CD271 and CD146 and displayed the clonogenic and multipotent functions were CD44Neg 
(26).  However, CD44 marker was acquired by CD44Neg subset after in vitro expansion. This finding is unexpected 
EHFDXVH&'KDVDOZD\VEHHQFRQVLGHUHGDVD³ZHOO-NQRZQ´06&VXUIDFHPDUNHULQH[SDQGHG-MSC studies 
(reviewed in Sousa et al (27)).  In agreement with Qian et al study, Busser et al confirmed the higher clonogenicity 
of the CD44Neg fraction in the BM (20). These authors also found that CD44Neg fraction showed greater osteogenic 
potential than the total unselected population, but in contrast, no differences in chondrogenic potential were 
found between CD44Neg and CD44+ cells (20). These authors also found greater osteogenic potential and 
clonogenic capacity in CD34+ than CD34Neg cells or unselected BM MSC population. Again, CD34Neg and CD34+ 
fractions did not show differences in the chondrogenic potential. As a result of different studies, CD34 had 
become another possible, but controversial marker for MSC subset selection from fresh BM aspirates (reviewed 
in Lin et al (28)).  
Functionally selected MSC subpopulations:  
Other approaches use cell division as functional parameter for identifying MSC subpopulations in early-
passage MSCs (29), or clonal expansion methods (8, 30). After clonal expansion, Dickinson et al performed a 
comparative analysis between greatest and poorest chondrogenic clones and found that the expression of ROR2 
positively correlated with chondrogenesis (30). In situ immunostaining corroborated the presence of ROR2+ cells 
co-located with CD146+ cells surrounding the blood vessels in the adult human BM. As mentioned, Espagnolle 
et al (8) performed a selection of the expanded clones based on CD146 expression, for further analysis. Other 
markers were used to study heterogeneity in culture-expanded MSCs, such as ganglioside-based membrane 
microdomains (31).  
Based on this information, it is fair to conclude that the existing literature supports the notion for at least 
two distinct topographies of MSCs in the BM (perivascular and bone-lining), however further work is needed to 
assess what effect these niches may have on MSC functionality assessed after their expansion and priming in 
vitro ,W LVSRVVLEOHWKDWVWDQGDUGFXOWXUHFRQGLWLRQV OHDGWR06&¶VFRQYHUJHQFHWRDFRPPRQSKHQRW\SH (32) 
therefore future investigations of BM MSC heterogeneity would benefit from a direct analysis of these cells 
immediately after purification. 
Pre-clinical studies with MSC cultures derived from selected subpopulations 
 Some selected BM subpopulations, mainly grown from CD271+ cells, have been evaluated in pre-clinical 
studies. In one study, CD271+ subpopulation of cultured BM MSCs when injected into infarcted murine heart, 
showed improved cardiac function (33). Another study reported improved repair of full thickness cartilage defects 
in rats using MSCs sorted for CD271+ and expanded to form cell pellets that were placed in and covered with 
atelocollagen sponges (34). Also, CD271-MSCs promoted significantly greater lymphoid engraftment than did 
plastic adherence-MSCs when co-transplanted with HSCs in immunodeficient mice (35). Other preclinical 
studies with BM MSC subpopulations have been recently reviewed in Mo et al (36) and Lv et al (37).    
1.2  Adipose tissue MSCs (ASCs) 
Location markers: CD146 and CD34 
Adipose tissue is a complex tissue of mesodermal origin that contains various cell types including adipose 
tissue MSCs, preadipocytes and mature adipocytes, fibroblasts, vascular smooth muscle cells, endothelial cells 
(ECs), monocytes/macrophages and lymphocytes (38). Obtaining MSC from adipose tissue, a waste product in 
several treatments, is popular due to the easy access to the tissue in large quantities. As for BM MSCs, two 
distinct MSC subsets have been discovered in human adipose tissue, but this time they are CD146+CD34Neg 
pericytes and CD146NegCD34+ adventitial cells (both negative for CD45) (39, 40). In situ immunostaining of 
adipose tissue obtained from abdominoplasty showed CD146NegCD34+ cells localized in the outer vascular ring 
and CD146+Į-SMA+ cells immediately adjacent to the vascular intima (39). In one study, a third population of 
CD146+CD34+ was observed with a very low frequency by flow cytometry (approximately 0.5% of the nucleated 
stromal vascular fraction cells), presumably a transitional population between the pericytic and supra-adventitial 
perivascular ring cells. Further studies are necessary to confirm these markers in situ. The frequency of these 
subsets differs significantly depending on donor demographics and the way of tissue processing, but is still 
unclear how these variables affect the different subsets.  
Other markers 
Bajek et al (41) studied the differences in early-passage ASC markers from tissues obtained either from 
mechanical or ultrasound-assisted liposuction, and they only found statistical differences in the expression of 
CD166. Other authors (20) did not found differences in CD166 expression that was low in both stromal cells from 
abdominoplasty and lipoaspirate, although they observed that CD271+ selected ASCs were highly proliferative 
and clonogenic only in lipoaspirate samples, being the contrary for abdominoplasty ones (CD271Neg fraction). 
Interestingly, CD271 marker was not mentioned in many characterization studies (42, 43). Importantly, Baer et 
al. (42) performed the first comprehensive phenotypic characterization of cultured adipose-derived stromal cells 
(ASCs) isolated from lipoaspirates. They found WKDW$6&VH[SUHVVHGWKHFKDUDFWHULVWLF06&¶VPDUNHUV&'
CD44, CD73, CD90, CD105 and CD166 but there was high donor variability for 49 of the 242 markers tested, 
including CD34 and CD200. These findings can be explained by the fact that CD271, as well as other molecules 
present on native adipose MSC subsets can be lost in culture. 
The difficulty in analyzing adipose tissue MSC literature is that adipose tissue is highly vascular and it is 
widely accepted that following digestion and removal of red cells, the remaining cells consist of leukocytes, 
stromal cells and ECs. Subsequent dissection of stromal cells and ECs is complicated by the fact that many 
'MSC' specific molecules - CD73, CD105, CD146 and some authors even consider CD90 - are also expressed 
on ECs (reviewed in Lin et al. (44)). Conversely, a typical endothelial progenitor molecule CD34 can be 
expressed on adipose MSCs (reviewed in Sidney et al. (45)), as stated above. So, these markers are not very 
useful alone for segregating MSCs from ECs however CD31NegCD45Neg combination can discriminate leukocytes 
and ECs from adipose MSCs as published by the ISCT together with the International Federation for Adipose 
Therapeutics and Science (IFATS) (43). These authors published a guidance for minimal criteria for stromal cells 
from adipose tissue, as previously performed for general MSC. This guide differentiates between freshly-isolated 
VWURPDO FHOOV DV ³XQFXOWXUHG VWURPDO YDVFXODU IUDFWLRQ´ 69) LGHQWLILHG PDLQO\ DV
CD45NegCD235aNegCD31NegCD34+ subset, and cultured stromal cells (ASCs), characterized as 
CD45NegCD31NegCD36+CD106Neg cells. Overall, the literature agrees that CD34+ may be present on a subset of 
native adipose MSCs, but it is lost in prolonged culture expansion (46) and is not useful as a sole marker as 
CD34 is also expressed on ECs and other cell types (44, 45). However, CD34 was considered a good marker 
for MSC enrichment from SVF fraction by Busser et al (20) as CD34+ ASCs were significantly more clonogenic 
and proliferative than parental cells. Furthermore, Bourin et al (43) observed that both SVF and ASCs express 
CD73, CD90 and CD105, although CD44 expression is only present in the cultured ASCs, which seems to be 
similar to CD44 pattern of expression on BM MSCs (26). Also, Bourin et al (43) suggested additional positive 
markers with variable expression, as CD146. Despite this, one study did not found expression of CD106 and 
CD146 markers in culture expanded-ASCs, but passage number at which cells were analyzed was not specified 
(47).   
Functionally selected MSC subpopulations 
Different from BM, Busser et al (20) found that adipose MSCs did not express SUSD2, MSCA-1/TNAP 
and CD44 in situ, but this data that needs to be confirmed. Hardy et al (48), performed enrichment of 
CD146+CD34Neg and CD146NegCD34+ subsets from adipose MSC tissue collected by lipoaspiration, focusing on 
the aldehyde dehydrogenase (ALDH) staining intensity. After culturing single-cell sorted cells, transcriptional 
profile analysis was done and ALDHbright cells were considered as the most primitive cell population within both 
subpopulations. Considering that this study was only performed using one sample, further confirmation is 
necessary.   
,Q JHQHUDO GLIIHUHQWO\ IURP %0 06&V PRVW RI WKH VWXGLHV XVLQJ DGLSRVH 06&V GRQ¶W VWXG\
chondrogenesis. There also exists controversy about MSC variability due to age, body mass index, niche location 
and the way of tissue processing that complicates data interpretation but may lead in the future to discovery of 
many more subtypes of adipose MSCs. For example, the possibility of finding different MSCs subpopulations 
that can support different types of blood vessels. So probably, different vascularity seen in lipoaspirates and 
solid fat tissues can be the reason for different types of MSCs found but more work is needed to study the 
relationship between these blood vessels and MSCs. Despite of all these unanswered questions, surprisingly, 
SVF are being used for clinical treatment of human cartilage damage (reviewed in Pak et al (49)).  
Pre-clinical studies with MSC cultures derived from selected subpopulations:  
In pre-clinical studies using AT MSCs, mainly CD34+, CD105+ and CD90+ subpopulations were tested. 
One study compared CD90+ and CD105+ subpopulations of cultured MSCs seeded on hydroxyapatite (HA)-
coated polylactic-co-glycolic acid (PLGA) scaffolds in calvarial defects in mice and showed better bone formation 
from CD90+ subpopulation (50). In calvarial defects in mice, cultures grown from CD105low sorted cells and 
seeded on HA-PLGA scaffolds formed more robust bone than cultures grown from CD105high cells (51). Other 
preclinical studies with selected AT MSCs have been reviewed in Johal et al (52).  
1.3 Synovial MSCs 
Location markers 
The synovial membrane is a specialized tissue of mesodermal origin lining the spaces of diarthrodial 
joints, bursae and tendon sheaths. It contains two compartments, the intima inner continuous cell compartment 
composed of fibroblast-like synoviocytes, and the subintima compartment composed of few macrophages and 
lymphocytes, fat cells, and blood vessels (53). Interestingly, the origin of synovium-derived MSCs in the synovial 
lining is still under investigation and can be related to infiltrated MSCs through vasculature or BM originated 
MSCs that connects to intra-articular space. Recently, two studies showed that single or double positive Prg4-
lineage and Gdf5-lineage cells, both present in the synovium, contribute to repair of articular cartilage injuries in 
mice (54, 55). Despite the hypothesis of the involvement of synovium-derived MSCs in cartilage repair is 
beginning to gain strength (56), in vivo and in vitro studies about synovium MSCs are scarce compared with 
MSCs from other tissues such as adipose or BM. A comprehensive review of clinical studies utilizing intra-
articular MSC therapy showed that only 7% of the studies reviewed used MSCs from synovial membrane (57). 
The same applies to in vitro studies, in which much fewer investigations were focused on synovial MSCs, mainly 
culture-expanded cells, compared to BM MSCs.   
In a pioneering study, Karystinou et al (58) reported for the first time the presence of cell subsets with 
distinct characteristics within the synovial membrane. They performed cell cloning by limiting dilution and found 
variations in MSC proliferation and potency: all clonal populations were chondro-osteogenic and only 33% of 
them were also adipogenic, unlike the parental MSC population that was tripotential. Phenotype evaluation of 
tripotential extensively-expanded clones by flow cytometry showed positivity for markers such as CD13, CD73, 
CD81, CD90, CD105, CD166 and SSEA-4. However, these authors did perform neither enrichment of these 
tripotential MSCs nor phenotypic analysis of bi-potential clones. Besides, in this study not all of the clones 
isolated were culture-expandable. Taking this into account and also the fact that markers as CD271 are 
undetectable after extensive expansion (59-61), recent studies are being focused in early-passage expanded 
(passages 0 to 1) or freshly-isolated MSCs. 
Hermida-Gomez et al (62) performed the first MSC topographic analysis of the synovial tissue, showing 
CD271+ cells present in its intima lining in healthy donors but also along vascular subintima in osteoarthritic 
patients, a likely route for the mobilization of the MSCs to reach the cartilage damage. However, other authors 
associated the increase of CD271+ MSCs in synovial membrane of arthritic patients with pro-inflammatory 
function (61). Hermida-Gomez et al (62) found that CD271+ cells present in synovium had a high co-expression 
of CD44 and CD90 but low levels of CD105. The low positivity of CD105 in addition to CD166, in freshly isolated 
synovial MSCs was confirmed by Jones et al (63) using flow cytometry. In spite of the low percentage of CD105+ 
MSCs present in synovial membrane, early-passage-CD105-selected cultures had good chondrogenic capacity 
after spheroid formation (64), but this study did not compare results with CD105Neg or total MSCs because these 
cells were not capable to form spheroids.  
More recently, Mizuno et al (65) proposed different phenotypes of MSC in the osteoarthritic synovium 
based on their topography: CD55+ MSCs in the surface region, CD271-CD55- in the stromal region and CD271+ 
in the perivascular region. However, these results need to be confirmed in healthy synovium.  
Other markers 
Another marker used for subsets analysis and enrichment from early-passage culture-expanded synovial 
MSCs was CD73, which enriched for cells with higher chondrogenic potency than CD106 marker (66). Also, 
CD44 expression was correlated with chondrogenic capacity (63), however no CD44 enrichment was performed 
in this study. Combinations of markers, such as CD73 and CD39 were later used for enrichment of synovial 
MSCs from early and late passages synovial cultures, and CD73+CD39+ subset was found to be more 
chondrogenic and osteogenic than CD73+CD39Neg subset (67). However, when these authors compared culture-
expanded and freshly isolated synovial cells they found no differences in clonogenicity and chondro-osteogenic 
potential between CD73+CD39+ and CD73+CD39Neg subsets confirming the necessity of performing this type of 
analysis using freshly isolated synovial cells. Furthermore, as commented above, markers such as CD271 are 
known to be downregulated following MSC culture-expansion; similarly CD34 marker was detected in directly 
isolated synovial cells, but declining following MSC passaging (60).   
To summarize, more work in this area is required to provide a convincing argument for the use of specific 
markers for the isolation of any functionally relevant subsets of synovial MSCs. To the best of our knowledge, 
no pre-selection of synovial MSC populations was performed in pre-clinical studies.  
Altogether, while MSC are being largely used in clinical trials as bulk-expanded heterogeneous 
preparations (reviewed in Squillaro et al (68), Kouroupis et al (69)), to our knowledge there is no clinical studies 
reported on a comparison between different selected subpopulations. In this area, an unanswered question yet 
remains: do phenotypically-same subpopulations from different tissues behave similarly upon implantation, or 
the tissues of origin, rather than phenotypes, are more important? 
 
2. MSC PRIMING 
Efficacy and reproducibility of MSC therapies are not only affected by the composition of the cell 
preparation (above), but also by the capacity of the transplanted cells to consistently reach and interact with 
dysregulated tissues (i.e., homing and engraftment) and subsequently to predictably induce and/or modify 
specific host responses (i.e., therapeutic effect). In other words, after administration (e.g., injection, infusion, 
etc.), MSCs have to migrate, home, engraft, survive, sense the local environment and reactively mount a 
paracrine reparative response. Previous studies have shown that systemically-infused MSCs (e.g., intravenous 
or intra-arterial administration) are capable of migrating and homing to distant sites of active injury including BM, 
intestine, liver and lung (11, 70-72). However, only a small percentage of infused cells (i.e., 0.1-2.7%) actually 
reaches the target tissues (73-78). Once at the injured tissue, it is well accepted that MSCs exert 
immunomodulatory (for both innate and adaptive immunity) and trophic activities (79, 80), recently suggested to 
EHFROOHFWLYHO\FDOOHG³PHGLFLQDO´ signaling activities (81, 82). These local activities are performed through both 
direct cell-cell communication (e.g., Notch receptor /Jagged-1 and PD-1/PD-L1/PD-L2 (83, 84)) and locally 
secreted paracrine mediators. The latter involves a list of chemokines released by MSCs including C-X-C motif 
chemokine 12 (CXCL12) (85), stem cell factor (SCF) (86), platelet-derived growth factor (PDGF) (87), 
traQVIRUPLQJJURZWKIDFWRUȕ7*)-ȕ) (88), vascular endothelial growth factor (VEGF) (88), tumor necrosis factor-
Įstimulated gene/protein 6 (TSG-6) (89), erythropoietin (EPO) (88), interleukin-6 (IL-6) (88), interleukin-10 (IL-
10) (88), indoleamine 2, 3-dioxygenase (IDO) (88) and prostaglandin E2 (PGE2) (90). Some of these factors 
(e.g., TSG-6) have been shown to also exert a remote paracrine therapeutic effect, demonstrated in myocardial 
infarction (91), lung injury (92), and corneal injury (93), suggesting that the induction of its secretion even without 
interaction with the target tissue might be sufficient for a therapeutic effect. On the other hand, host tissue 
conditions (e.g., age and disease) also have an effect on the paracrine activity of engrafting MSCs (94-96). For 
instance, elevated levels of proteases such as elastase, cathepsin, and dipeptidylpeptidase (DPP) present in the 
aged tissue destabilize trophic factors induced by MSCs. Interestingly, the administration of a pharmacologic 
inhibitor of DPP prior the therapy enhanced the stability of CXCL12 and increased the engraftment and function 
of CXCR4+ progenitor cells in an acute myocardial infarction mouse model (97).  Collectively, this evidence 
suggests that both the ³SKDUPDFRNLQHWLF´SURSHUWLHVDQGtherapeutic activity of MSCs can be modulated and/or 
boosted a priori, through multiple ex vivo priming protocols. We now discuss a few techniques proposed to 
effectively prime MSCs before their transplantation in vivo (Figure 2).  
2.1. Membrane and cytoplasmic MSC priming 
MSCs express a variety of membrane adhesion molecules including intercellular adhesion molecules-1 
and 2 (ICAM-1 and ICAM-2), vascular cell adhesion molecule-1 (VCAM-1), L-selectin, CD18, CD24, CD29, 
CD44, and CD49a-f (98, 99). Previous studies have shown that the adhesion molecule expression profile 
presents an intra-population heterogeneity (71), which is not only determined by the tissue of origin (100) but 
also by isolation and culture procedures. For instance, Aldridge et al., showed that early and late passaged 
MSCs have different adhesion molecule profiles, with CD49d exhibiting variable expression within the same cell 
population (71). Despite the potential deleterious effect this variability may have on cell adhesion processes, 
MSCs¶ homing to target sites can be enhanced through diverse in vitro membrane modification techniques that 
incorporate natural and induced processes such as: a) the hematopoietic stem cell/leukocyte transendothelial 
migration process (i.e., diapedesis); b) chemical or non-covalent interactions; and c) biospecific recognition. 
Early evidence has shown that engineering transmembrane glycoproteins on MSCs using characterized selectin 
ligands affects MSC migration through vasculature after systemic infusion in vivo, similar to leukocytes 
extravasation to inflamed tissues (101). Ruster et al. identified that MSCs, like leukocytes, roll and adhere to 
postcapillary venules via cellular interactions with ECs engaging P-selectin as well as VCAM-1/(CD106) - VLA-
4(CD49d/CD29) pathways (102, 103). As MSCs do not express P-selectin ligands such as glycoprotein ligand-
1 (PSGL-1/CD162) or CD24, alternative ligands have been proposed (e.g., CD44 glycoprotein which binds 
hyaluronic acid)(104).  
Hematopoietic cell E-/L-selectin ligand (HCELL), a specific isoform of CD44 that binds strongly E-selectin 
(105), has been associated with MSC homing to BM in vivo (106) and thus its modification constitutes a promising 
approach to enhance that process. Using enzymatic conditions, Sackstein et al. (104) converted the MSC 
membrane native CD44 glycoprotein into HCELL allowing their efficient binding to E-selectin. The resulting 
sialofucosylated glycan moiety on CD44 is known as Sialyl-Lewis X (SLex), the active selectin-binding 
carbohydrate motif site for HCELL. Interestingly, intravenously infused HCELL+ MSCs infiltrated mouse BM 
within hours of infusion (104). Enzymatic membrane modification targets only glycoproteins that already exist on 
the surface of MSCs, whereas further chemical alterations enable the cells to present several epitopes via 
covalent bioconjugation method, potentially enhancing the effect. Importantly, Sarkar et al. used several 
approaches to covalently attach SLex on MSC membrane through biotin-streptavidin binding, conferring 
leukocyte-like rolling characteristics to MSCs without affecting their phenotype and multilineage differentiation 
capacity (107, 108). These approaches resulted in increased MSC rolling on P-selectin at a physiological shear 
of 0.5 dyn/cm2 in vitro. In an ear inflammation mouse model, SLex engineered MSCs exhibited a robust rolling 
response on inflamed endothelium (109).  
Another method to improve MSC homing is via antibody conjugation approach. To localize MSCs at a 
target tissue, researchers have used palmitated protein G or A pre-coating of the cell membrane as a step to 
bind antibodies on the MSC surface. Interestingly, Dennis et al. (110) have pre-coated the membrane of MSC 
chondrogenic progenitors with palmitated protein G and bound to the protein G antibodies specific for cartilage 
matrix antigens. Effective homing of membrane modified chondrogenic progenitors was observed to cartilage 
injury site in rabbit osteochondral explants (110). In another study, homing rate and repairing efficacy of MSCs 
improved using anti-CD29 and anti-myosin light chain bispecific antibodies in a mouse myocardial fibrosis model 
(111). Importantly, in this study Deng et al. (111) also used highly focused ultrasound mediated stimulation of 
micro-bubbles, which significantly increases homing of MSCs to the mouse injured myocardium (112). Finally, 
another non-conventional method to enhance MSC homing is the internalization of superparamagnetic iron oxide 
nanoparticles with exogenously-guided magnetic targeting. This approach has been used by two separate 
studies showing enhanced MSC homing to mouse retina (113) and tail (114) and rabbit and swine osteochondral 
defects (115). 
2.2. Cytokine and hormonal priming of cultured MSCs 
An alternative approach to enhance homing and therapeutic capacity of MSCs is to prime the cells with 
specific cytokines and growth factors. Shi et al. showed that MSC priming with a cytokine cocktail containing 
SCF, HGF, IL-3 and IL-6 increases their CXCR4 expression (116). As a result, CXCR4 upregulation enhanced 
MSC chemotaxis to CXCL12 in vitro and homing efficiency to BM in vivo. Similarly, IL-1ȕ-primed MSCs exhibited 
an enhanced homing capacity to inflammatory sites in an ulcerative colitis mouse model, also via upregulation 
of CXCR4 (117). Mechanistically, IL-1ȕ-primed MSCs express multiple cytokines including TNF-Į, IL-6, IL-8, 
IL23A, IL32 and chemokines CCL5, CCL20, CXCL1, CXCL3, CXCL5, CXCL6, CXCL10, CXCL11 and CX3CL1, 
as well as MMPs and adhesion molecules ICAM-1 and ICAM-4 (118). Interferon-Ȗ (IFNȖ) is another molecule 
widely used to prime MSCs.  It is a major pro-inflammatory mediator that has been shown to increase MSCs 
homing capacity to inflamed intestine in an ulcerative colitis mouse model, by upregulating CXCR7 and lectins 
LGALS3BP and LGALS9 in infused cells (119). A major effect of IFNȖ relies on the induction of the expression 
and activity in MSCs of the enzyme indoleamine 2,3-dioxygenase (IDO), involved in the direct suppression of T 
cells proliferation and activation (120, 121). IFNȖ priming also upregulates the production of IL- 6 in MSCs (122), 
a cytokine with known anti-inflammatory and reparative effects in vitro and in vivo (e.g., liver fibrosis mouse 
model (123)). Therefore, due to its high potency in inducing immunomodulatory factors, IFNȖ has been proposed 
by many studies as a priming cytokine to enhance MSCs efficacy in vivo.  Other priming methods with positive 
effects include exposure to complement component 1 subcomponent q (C1q), which enhances MSC homing by 
inducing chemotactic responses to SDF-1 gradient. Glycogen synthase kinase 3ȕ (GSK-3ȕ) inhibitors have also 
been used for MSC priming, resulting in increased MSC migration via the upregulation of  ȕ-catenin, phospho-
c-Raf, ERK, phospho-ȕ-PAK-interacting exchange factor (124), enhancing CXCR4, MMP-1 and MMP-2 
expression. 
 Hormonal priming of MSCs has been proposed as an additional method to improve MSC survival and 
to induce paracrine actions post-transplantation in vivo in various conditions such as myocardial infarction 
(125) and brain injury (126). Mias et al. also showed that MSCs primed with melatonin stimulated angiogenesis 
and proliferation of renal proximal tube cells in vitro via increased HGF and FGF-2 expression, and accelerated 
renal recovery in vivo following similar mechanisms and increased cell survival after transplantation (127). 
Melatonin MSC priming also showed beneficial effects in focal cerebral ischemia in rats, where it not only 
increased MSC survival post-transplantation in vivo, but also reduced brain infarction and increased 
angiogenesis and neurogenesis (126). On the other hand, oxytocin-primed MSCs reduced cardiac fibrosis and 
macrophage infiltration while enhanced cardiac repair for at least 4 weeks post-MSC transplantation in vivo 
(125). In a recent study, Liu et al. (128) showed that angiotensin-II hormone MSC priming results in reduced 
cardiac fibrosis and infarct size, improved cardiac function, increased expression of VEGF and von Willebrand 
factor in the ischemic myocardium but no MSC differentiation towards cardiomyocytes in vivo.   
2.3. Hypoxia priming of cultured MSCs 
Rapid loss of implanted MSCs in vivo has been associated with hypoxic stress at the ischemic target 
tissue, which can initiate cellular apoptosis (129). It is worth mentioning that MSCs are typically cultured at a pO2 
level of 142 mmHg (~20%), while the oxygen tension in the BM niche ranges from 1% to 7%, and in ischemic 
tissues from 0.4% to 2.3% (130). In a pioneering study, Annabi et al. identified that hypoxic environments (i.e., 
1% oxygen, 5% CO2, 94% nitrogen) induce in vitro MSC migration and three-dimensional capillary-like structure 
formation through the secretion of VEGF and MMP-1 (131). Moreover, this increased migratory behavior is 
explained by Akt signaling activation and induction of cMet expression, the main receptor of HGF (132), whereas 
the promotion of the MSC-dependent angiogenic effect is directly associated with the activation of hypoxia-
inducible factor-1Į (HIF-1Į)-78-kDa glucose-regulated protein (GRP78)-Akt signaling pathway (133). In general, 
MSC priming under hypoxia enhances the upregulation of several signaling molecules including CXCR4 (134-
136), CX3CR1 (134), CXCL-12 (134, 135), VEGF (135) and vascular endothelial growth factor receptor-2 
(VEGFR-2) (135), MMP-2 (136), MMP-9 (136), brain-derived neurotrophic factor (BDNF)(135), glial cell-derived 
neurotrophic factor (GDNF) (135), erythropoietin (EPO) (135) and its receptor EPOR (135), focal adhesion 
kinase (FAK) (137). The in vivo administration of hypoxia-primed MSCs show increased homing capacity, 
enhanced vascularization and restored function in various ischemic conditions, including myocardial infarction, 
cerebral and hind limb ischemia (132, 134-137). Mechanistically, two separate studies in mouse and rat 
myocardial infarction models showed that hypoxia-primed MSCs improve infarcted heart function via enhanced 
survival of implanted MSCs, increased angiogenesis and prevention of cardiomyocyte apoptosis through cell 
survival factor secretion (138, 139). These results were extended to diabetic cardiomyopathy, in which anoxia-
primed MSCs improved cardiac function through not only anti-apoptotic effects but also attenuation of cardiac 
remodeling (140). In acute kidney injury, hypoxia-primed MSCs showed beneficial effects by improving renal 
function, increasing angiogenesis and reducing the levels of pro-inflammatory cytokines (141, 142).  
Even though hypoxia-derived MSC priming has a positive influence on migration and homing capacities 
in several conditions, there is evidence of potential unwanted effects that require further investigation and that 
may indicate that hypoxia-priming may be application specific. This includes a negative effect on MSC 
osteogenic differentiation capacity (143), and the accumulation of reactive oxygen species (ROS) that alter their 
transcriptional factor profile (144). In contrast, Estrada et al. showed that low oxygen levels enhance cell 
proliferation and genetic stability by favoring a natural metabolic state of increased glycolysis and reduced 
oxidative phosphorylation (145). Therefore, further studies should carefully consider the long-term effects of 
hypoxia primed MSCs in models of disease.  
2.4. Induction of specific functional MSC phenotypes 
One of the main therapeutic mechanisms of MSCs at the target site is to immunomodulate local 
responses (80, 146). However, depending on the molecular composition of the instructive environment at the 
injury site, interacting MSCs exhibit a therapeutic responsive polarization into either anti-inflammatory (MSC-2) 
or pro-inflammatory (MSC-1) phenotypes, tightly coupled to M2/M1 macrophage skewing (147, 148). Toll-like 
receptors (TLRs) are the most studied pattern recognition receptor family in MSCs, which sense pathogen-
associated molecules involved in the regulation of innate immunity. Previous studies indicate that human MSCs 
consistently express TLR1, TLR2, TLR3, TLR4, TLR5, and TLR6, whereas TLR7, TLR8, TLR9, and TLR10 
expression is dependent on the MSC origin (149-153). As elaborated below, several studies indicate that 
activation of specific TLRs in MSCs in vitro prior transplantation has a profound effect on the immunomodulatory 
capacities of MSCs. TLR3 and TLR4 are particularly important IRU06&V¶GRZQVWUHDPHIIHFWVZKLFK can be in 
vitro activated by dsRNA mimetic polyinosinic-polycytidylic acid (i.e., poly(I:C)) and lipopolysaccharide (LPS), 
respectively (147).  Waterman et al. showed that TLR3 stimulation of MSCs supports their immunosuppressive 
effects preferentially through enhanced fibronectin deposition, whereas TLR4 stimulation of MSCs provides a 
more pro-inflammatory signature in part through release of TGF-ȕ and collagen deposition (147). In that respect, 
low-dose of poly(I:C) for 24h results in TLR3 activation and induction of VEGF, CXCL12, IL-6, IL-10, IL-11, 
leukemia inhibitory factor (LIF) and HGF without upregulation of inflammatory cytokines (154). Therefore, it is 
not surprising to observe that injection of poly(I:C)-treated MSCs in a hamster heart failure model, resulted in 
cardiac functional improvement with a 50% reduction in myocardial fibrosis, 40% reduction in apoptosis and 55% 
increase in angiogenesis (154). On the other hand, a recent study showed that both TLR3 and TLR4 activation 
comparably enhance MSC-mediated T regulatory cells (i.e., Tregs) induction through Notch signaling and 
upregulation of Delta-like 1 (DL1), critical cellular mechanisms for the immunomodulatory properties of MSCs 
(155). In a rat acute myocardial infarction model, Yao et al. showed that LPS-dependent  priming results in 
increased MSC survival post-transplantation in vivo, coupled with reduced fibrosis of the infarcted myocardium, 
increased neovascularization and earlier recovery of the cardiac function (156). Transcriptional profiling of LPS-
primed MSCs showed that several chemokines, cytokines and adhesion molecules were highly up-regulated 
including CXCL10, CCL20, IL8, CXCL1, IL6, CCL2, IL1B, CXCL2, IL1A, CXCL6, ICAM1, VCAM1, and SELE 
(157). 
Different studies have indicated contrasting effects of TLR activation on MSC multi-differentiation 
potential. In a comparative study performed by Raicevic et al., TLR activation of MSCs with post-natal and 
perinatal origin resulted in differential osteogenic potential depending on MSC tissue of origin (158). TLR2 and 
TLR4 activation in umbilical cord blood-derived MSCs promote chondrogenesis and osteogenesis with different 
intensities, whereas adipogenic differentiation is not altered by such TLR activation (159). MSCs harvested from 
the umbilical cord showed differential responses in terms of osteogenic potency, with TLR4 activation increasing 
and TLR3 activation decreasing it, respectively (160). On the contrary, both TLR3 and TLR4 downstream 
signaling promote BM-MSCs¶ osteogenic potency (161), through activation of Wnt3Į and Wnt5a signaling (TLR4) 
(162). Several groups have reported comparable increased osteogenic potency with activation of TLR2-, TLR3, 
TLR4- primed adipose tissue MSCs (ASCs) with unaffected adipogenesis (149, 163). A novel pattern recognition 
receptor, the triggering receptor expressed on myeloid cells (TREM), identified to regulate myeloid cells function 
in vitro (164), has been associated also with MSCs. Zhang et al. indicated that one of TREM family members, 
TREM-2, is expressed in MSCs and its knockdown reduces TLR2, TLR4, and TLR6 expression, impairing 06&V¶
multi-differentiation potential (165). Thus, we could speculate that TREM-2 ligands would induce TLR-specific 
responses in favor of cell differentiation. 
2.5. Priming MSCs in 3D spheroid cultures 
Adult MSCs possess a remarkable ability to coalesce and assemble in tri-dimensional (3D) structures, 
reminiscent of their innate aggregation as limb cell precursors in the mesenchymal condensation during early 
skeletogenesis. In that context, 3D organoid formation in vitro closely recapitulates the in vivo MSC niche by 
providing spatial cell organization with increased cell-cell interactions. As a matter of fact, MSCs cultured in 3D 
spheroid cultures show stable immuno-phenotypic profile, with a significant enhancement in survival (166), 
homing (167), stemness features (168, 169), differentiation potential (168, 169), angiogenic effect (166) and anti-
inflammatory properties(170). For example, in a mouse model of hind limb ischemia, MSC transplantation as 3D 
spheroids improved their survival compared with 2D expanded MSCs, by suppressing a key apoptotic signaling 
molecule (Bax), while activating anti-apoptotic signaling (BCL-2) (166). These positive effects can also be 
attributed to improved resistance to oxidative stress-induced apoptosis exerted by hypoxia-induced genes (e.g., 
VEGF-A, HIF-1Į and MnSOD), elevated by the hypoxic conditions at the spheroid core (171, 172).  
Additional benefits of 3D cultures account for the established reduction in size of individual MSCs (about 
0.25 to 0.5 the volume of an average 2D cultured cell), which reduce cell entrapment in the lungs when 
systemically infused (170). MSCs stemness features are also improved in 3D MSC spheroid cultures, evidenced  
by: 1) higher expansion and colony-forming activities (169); 2) enhanced differentiation capacities (168, 173, 
174); and 3) changes in the epigenetic status of genes indicative of a more pluripotent nature (NANOG, SOX2, 
OCT4) (168). As expected given the presence of a stimulating variable oxygen tension within the spheroids, 
angiogenic properties of MSCs are positively affected by 3D spheroid priming. This trophic enhancement is 
produced via upregulation of key angiogenic factors including VEGF, HGF, FGF-2, angiogenin (ANG), and 
angiopoietin 2 (ANGPT-2) (167, 172, 175). Murphy et al. showed that MSC spheroids embedded in fibrin gel 
secrete up to 100-fold more VEGF compare to dissociated MSCs in fibrin gel (176). Additionally, other groups 
have reported an increased homing capacity of MSC spheroids through a significant upregulation in the 
expression of the CXCL12 chemokine receptor CXCR4 (167, 169).  Enhanced anti-inflammatory effects of 3D 
cultures have been reported by previous studies indicating that MSC spheroid highly express TGF-ȕ1, IL-6, TSG-
6, stanniocalcin (STC-1), and PGE-2 anti-inflammatory molecules (170, 177, 178). As mentioned earlier, MSCs 
acquire effective anti-inflammatory properties after being primed with pro-inflammatory cytokines. Interestingly, 
Bartosh et al. showed that MSC aggregation into 3D spheroids activates the expression of IL-1 in an autocrine 
secretion manner, thus initiatLQJDQ³DXWR-SULPLQJ´HIIHFW (170). Contrarily, Redondo-Castro et al. reported that 
the combination of IL-1 stimulation with spheroid priming resulted in significantly increased expression of IL1-
Ra, VEGF and G-CSF molecules without anti-inflammatory effects on LPS-treated microglial cells in co-cultures 
(179). The discrepancies of the data underline the necessity for optimization of the priming methods and culture 
conditions. As a recent effort, Ylostalo et al. proposed specific protocols to efficiently prime MSCs in 3-D cultures 
under chemically defined xeno-free  conditions and how to administer the primed MSCs in vivo (180).   
Finally, MSC-based 3D spheroids have been applied in various preclinical models including wound 
healing (171, 181), bone and osteochondral defects (182-184) and cardiovascular diseases (185, 186). Two 
separate groups applied MSC spheroids for wound healing in chemotherapy-induced oral mucositis (171) and 
in a model of diabetic healing impaired (leptin receptor-deficient mice) (181). In both cases MSC spheroid group 
provide better therapeutic efficacy compared with traditional MSC suspension group. Using a rat calvarial defect 
model, MSC spheroids implantation resulted in full-thickness bone formation that efficiently filled the generated 
bone defects (184). Intramyocardial transplantation of MSC spheroids in rat (185) and porcine (186) myocardial 
infarction models resulted in greater heart function improvement compared with MSC suspensions.  
Collectively, MSC priming strategies aim to yield cellular products of high quality and potency by 
enhancing homing, survival, stemness, differentiation, anti-inflammatory and other MSC properties (Figures 2 
and 3). As mentioned before, various methods exist to manipulate MSC properties that possess advantages and 
disadvantages mainly related to the quality of the cellular product (Table 7).  
 
3. Clinical studies using functionalized MSCs  
Up-to-date no clinical trials have been executed to evaluate the efficacy of MSC subpopulations. On the 
other hand, three clinical trials are currently registered in www.clinicaltrials.gov using primed MSC. Despite the 
fact that various priming methods have been developed to enhance MSC properties in vitro, some with  
preclinical validation, the current clinical studies center on hypoxia/ischemia as the priming method to enhance 
06& WURSKLF SURSHUWLHV 7KH SKDVH  µ67$57,1*-¶ VWXG\ 1&7 HYDOXDWHV WKH HIILFDF\ RI
intravenously infused autologous BM-derived MSCs pre-conditioned wiWKDXWRORJRXV³LVFKHPLFVHUXP´WRWUHDW
stroke patients. A phase 1/2 study (NCT01849159) investigates the effectiveness of intravenously infused 
allogenic BM-derived MSCs primed in vitro under 1% hypoxia to regenerate the lungs of patients suffering from 
pXOPRQDU\ HPSK\VHPD )LQDOO\ WKH µ73$$%3,+'¶ SKDVH  VWXG\ NCT02504437) investigates hypoxia-
primed autologous BM-derived MSCs for their effectiveness to treat patients with ischemic heart diseases. 
Consequently, additional clinical research is needed tRDVVHVVWKHVDIHW\DQGHIILFDF\RI³IXQFWLRQDOHQKDQFLQJ´
strategies to MSC before administration, including cell selection and priming protocols.         
4. Conclusions 
It has become increasingly clear that current MSC culture-expansion methods, although proven to be 
clinically safe, do not guarantee the preservation of specific native MSC characteristics and attributes, thus 
yielding cell-based products of variable quality, and more importantly, potency. This in addition to inherent 
differences secondary to various factors including: origin of the cells (i.e., autologous or allogeneic), donor age 
DQGXQGHUO\LQJSDWKRORJLFDOFRQGLWLRQVDQGWKHUHFLSLHQW¶VLPSODQWDWLRQVLWHPLFURHQYLURQPHQW7KHUHVXOWLQJ
compromised standardization may account for the observed inconsistent therapeutic outcomes. Therefore, 
obtaining more homogeneous MSC preparations (e.g., through selection and/or induction by priming) in which 
the critical features are preserved may help circumvent the lack of reproducibility while enhancing their 
therapeutic effects (Figure 3). Thus, based on pre-clinical data, MSC subpopulation(s) selection and priming 
protocols may offer therapeutic advantages compared with the use of bulk/heterogeneous preparations in a 
number of clinical indications.  
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FIGURE LEGENDS: 
 
Figure 1: MSC topography within bone marrow. All BM MSCs are CD271+, whereas CD146 and CD56 help 
discriminate their differential presence within two distinct anatomical regions of the BM: 1) the perivascular niche 
(CD146+) where they interact with blood vessels (arterioles and sinusoids), and 2) the bone-lining niche 
(CD146Neg CD56+) where they interact with cells of the osteoblastic lineage (quiescent bone lining cells and 
active osteoblasts in places of active remodeling). 
 
Figure 2: MSC priming strategies include membrane modification, cytokine and hypoxia priming, Toll-like 
receptor priming, and 3D spheroid priming 
 
Figure 3: MSC functionalization by priming in 2D and 3D cultures results in boosted homing, immunomodulatory 
and trophic effects in vivo.  
Table 1. Membrane and cytoplasmic MSC priming 
 
 
 
 
 
 
 
 
 
 
 
PRIMING 
METHOD REFERENCE 
TYPE OF 
CELLS 
TYPE OF 
PRIMING PRECLINICAL MODEL OUTCOME IN VIVO 
Membrane 
priming 
Xia L et al., 2004 
(197) 
Human 
umbilical 
cord blood 
CD34+ 
cells 
Enzymatic 
functionalization 
with selectin-
binding motifs 
Non-obese 
diabetic/severe combined 
immune deficiency 
(NOD/SCID) mouse model 
Systemically administered functionalized-
CD34+ cells showed increased bone marrow 
homing 
Membrane 
priming 
Sackstein R et al., 
2008 (106) 
Human 
BM MSCs 
Enzymatic 
convertion of 
native CD44 into 
haematopoietic cell 
E-/L-selectin ligand 
(HCELL) 
Non-obese 
diabetic/severe combined 
immune deficiency 
(NOD/SCID) mouse model 
Intravenously infused HCELL (+) MSCs 
infiltrated marrow within hours of infusion 
Cytoplasmic 
priming 
Kobayashi T et al., 
2008 (117) 
Human 
BM MSCs 
MSCs labeled with 
internalized 
superparamagnetic 
iron oxide 
nanoparticles 
(SPIONs) 
Rabbit and Swine 
osteochondral defect 
models 
Local knee administration of SPIONs-
labelled MSCs showed increased homing at 
the osteochondral defect sites 
Membrane 
priming 
Ghanem A et al., 
2009 (114) 
Human 
BM MSCs 
Combination of BM 
MSCs with 
ultrasound 
mediated 
stimulation of 
micro-bubbles 
Acute myocardial 
ischemia and reperfusion 
rat model 
MSCs migrate across the myocardial 
endothelium whereas micro-bubbles 
stimulation improves MSC myocardial 
engraftment and allows locoregional 
targeting of post-ischemic myocardium 
Membrane 
priming 
Sarkar D et al., 
2011 (111) 
Human 
BM MSCs 
Conjugation of the 
sialyl Lewisx (sLex) 
PRLHW\WR06&V¶
surface through 
biotin-streptavidin 
Ear inflammation BALB/C 
mouse model 
Systemically administered SLex engineered 
MSCs exhibited a robust rolling response on 
inflamed endothelium 
Membrane 
priming 
Deng W et al., 
2011 (113) 
Mouse 
BM MSCs 
Combination of BM 
MSCs  with anti-
CD29/anti-myosin 
light chain 
bispecific 
antibodies and 
ultrasound 
mediated 
stimulation of 
micro-bubbles 
Isoproterenol-induced 
myocardial fibrosis mouse 
model 
The homing rate to injured myocardium and 
repairing efficacy of systemically 
administered MSCs improved 
Cytoplasmic 
priming 
Yanai A et al., 
2012 (115) 
Rat BM 
MSCs 
MSCs labeled with 
internalized 
superparamagnetic 
iron oxide 
nanoparticles 
(SPIONs) 
Retinal degeneration rat 
model 
Increased retina homing of SPIONs-labelled 
MSCs after both systemic and intravitreal 
infusions under magnetic field 
Cytoplasmic 
priming 
Landázuri N et al., 
2013 (116) 
Human 
BM MSCs 
MSCs labeled with 
internalized 
superparamagnetic 
iron oxide 
nanoparticles 
(SPIONs) 
Mouse model 
Systemically administered SPIONs-labelled 
MSCs showed increased tail homing under 
magnetic field 
Table 2. Cytokine MSC priming 
 
 
 
 
 
 
 
 
 
 
PRIMING 
METHOD REFERENCE 
TYPE 
OF 
CELLS 
TYPE OF 
PRIMING PRECLINICAL MODEL OUTCOME IN VIVO 
Cytokine 
priming 
Shi M et al., 2007 
(118) 
Human 
fetal BM 
MSCs  
MSC priming with 
SCF, HGF, IL-3 
and IL-6 cocktail 
Sublethally irradiated non-
obese diabetic/severe 
combined immune deficiency 
(NOD/SCID) mouse model 
Short-term (24 hours) MSC priming with the 
cytokine cocktail resulted in up-regulation of 
CXCR4 and increased MSC homing to the 
BM post-intravenous infusion  
Cytokine 
priming 
Hahn JY et al., 2008 
(198) 
Rat BM 
MSCs 
MSC priming with 
FGF-2, IGF-1 and 
BMP-2 cocktail 
Myocardial infarction rat 
model 
Local transplantation of cytokine primed 
MSCs resulted in enhanced gap junction 
formation, smaller infarct size and better 
cardiac function than untreated MSC group 
Cytokine 
priming 
Fan H et al., 2012 
(119) 
Human 
Umbilical 
cord 
MSCs  
IL-1ȕ-primed 
MSCs 
Dextran sulfate sodium 
(DSS)-induced ulcerative 
colitis mouse model 
Intravenously infused IL-ȕ-primed MSCs 
modulated the balance of immune cells in 
the spleen and the mesenteric lymph nodes 
(MLNs) and possessed an enhanced 
homing capacity to inflammatory gut site via 
upregulation of CXCR4 
Cytokine 
priming 
Duijvestein M et al., 
2011 (121) 
Human 
BM 
MSCs 
Interferon-Ȗ,)1-
Ȗ-primed MSCs 
Dextran sodium sulfate 
(DSS)- and trinitrobenzene 
sulfonate (TNBS)-induced 
ulcerative colitis mouse 
model 
Intraperitoneally infused IFNȖ-primed MSCs 
show upregulated CXCR7, LGALS3BP, 
LGALS9 expression and increased homing 
to the inflamed intestines  
Cytokine 
priming 
Nasir GA et al., 
2013 (125) 
Mouse 
BM 
MSCs 
Hepatic 
microenvironment 
priming with IL-6 
intraperitoneal 
injections 
combined with 
MSC 
transplantation 
Carbon tetrachloride (CCl4) 
fibrotic liver mouse model 
In vivo hepatic microenvironment priming 
with IL-6 resulted in increased MSCs homing 
to fibrotic liver and reduced fibrosis and 
apoptosis post-local liver MSC 
transplantation 
Cytokine 
priming 
Cheng W et al., 
2017 (199) 
Rat BM 
MSCs 
IL-25-primed 
MSCs 
Dextran sodium sulfate 
(DSS)- induced ulcerative 
colitis rat model 
Intravenously infused IL-25-primed MSCs 
exert improved therapeutic effects on the 
intestinal inflammation which may be related 
to the inhibition of Th17 immune response 
and induction of T regulatory cell phenotype 
Cytokine 
priming 
Aktas E et al., 2017 
(200) 
Rat BM 
MSCs 
TNF-a primed 
MSCs 
Achilles tendon segmental 
defect rat model 
- TNF-a-primed MSCs reduced IL-12 
production and the number of M1 
macrophages, whereas increased the 
percent of M2 macrophages, and synthesis 
of the anti-inflammatory factor IL-4 
- Concentration of type I procollagen in the 
healing tissue and failure stress of the 
tendon were increased 4 weeks post-injury 
Cytokine 
priming 
Guess AJ et al., 
2017 (201) 
Human 
and 
Mouse 
BM 
MSCs 
Interferon-Ȗ,)1-
Ȗ-primed MSCs 
Total body irradiated mouse 
model 
Intravenously infused IFNȖ-primed MSCs 
supported hematopoietic reconstitution 
without evidence of organ toxicity or tumor 
formation 
Cytokine 
priming 
Kim DS et al., 2018 
(202) 
Human 
BM 
MSCs 
Interferon-Ȗ,)1-
Ȗ-primed MSCs 
Graft-versus-host disease in 
an immune deficiency 
(NOD/SCID) mouse model   
Intravenously infused IFNȖ-primed MSCs 
effectively decreased clinical symptoms and 
immune cell infiltration into the skin and 
small intestine of GVHD mice, improving 
their survival rate  
Table 3. Hormonal MSC priming 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRIMING 
METHOD REFERENCE 
TYPE OF 
CELLS 
TYPE OF 
PRIMING PRECLINICAL MODEL OUTCOME IN VIVO 
Hormonal 
priming 
Mias C et al., 2009 
(129) 
Rat BM 
MSCs 
Melatonin 
priming Acute kidney injury rat model 
Intra-parenchymal injection 
of melatonin primed MSCs 
resulted in increased MSC 
survival, angiogenesis, 
proliferation of renal cells 
and accelerated renal 
recovery 
Hormonal 
priming 
Kim YS et al., 2012 
(127) 
Human 
UC 
MSCs 
Oxytocin 
priming  
Myocardial infarction rat 
model 
Intramyocardial injection of 
oxytocin primed MSCs 
reduced cardiac fibrosis 
and macrophage infiltration 
and enhanced cardiac 
repair for at least 4 weeks 
post-MSC transplantation in 
vivo 
Hormonal 
priming 
Tang Y et al., 2014 
(203) 
Rat BM 
MSCs 
Melatonin 
priming 
Focal cerebral ischemia rat 
model 
Melatonin primed MSCs 
were stereotactically 
injected into the striatum of 
the ipsilateral hemisphere. 
Melatonin MSC priming 
increased MSC survival in 
vivo, whereas melatonin 
primed MSCs reduced 
brain infarction, increased 
angiogenesis and 
neurogenesis.  
Hormonal 
priming 
Liu C et al., 2015 
(131) 
Rat BM 
MSCs 
Angiotensin-II 
priming 
Myocardial infarction rat 
model 
Angiotensin-II hormone 
MSC priming results in 
reduced cardiac fibrosis 
and infarct size, improved 
cardiac function, increased 
expression of VEGF and 
von Willebrand factor in the 
ischemic myocardium but 
no MSC differentiation 
towards cardiomyocytes 
after intra-myocardial 
injection in vivo 
Table 4. Hypoxia MSC priming 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRIMING 
METHOD REFERENCE 
TYPE OF 
CELLS 
TYPE OF 
PRIMING PRECLINICAL MODEL OUTCOME IN VIVO 
Anoxia 
priming 
Uemura R et al., 
2006 (142) 
Mouse 
BM MSCs 
Hypoxic gas 
mixture MSC 
priming 
Myocardial infarction mouse 
model 
Anoxia primed MSCs improved 
infarcted heart function via 
enhanced survival of implanted 
MSCs and prevent left 
ventricular remodeling of 
ischemic heart through MSC 
paracrine signaling 
Hypoxia 
priming 
Hung SC et al., 
2007 (137) 
Human 
BM MSCs 
Hypoxic gas 
mixture MSC 
priming 
Xenotypic grafting early chick 
embryo model 
Hypoxia primed MSCs showed 
increased homing capacity into 
early chick embryos and 
generated a variety of cell 
types in host tissues 
Hypoxia 
priming 
Rosová I et al., 
2008 (135) 
Human 
BM MSCs 
Hypoxic gas 
mixture MSC 
priming 
Non obese diabetic/severe 
combined immune deficiency 
(NOD/SCID) hind limb 
ischemia mouse model  
Intra-arterial injected hypoxia 
primed MSCs increased locally 
muscle revascularization 
Hypoxia 
priming 
Hu X et al., 2008 
(143) 
Mouse 
BM MSCs 
Hypoxic gas 
mixture MSC 
priming 
Myocardial infarction mouse 
model 
Hypoxia primed MSCs improve 
infarcted heart function via 
enhanced survival of implanted 
MSCs and increased 
angiogenesis 
Anoxia 
priming 
Li JH et al., 2008 
(144) 
Rat BM 
MSCs 
Hypoxic gas 
mixture MSC 
priming 
Diabetic cardiomyopathy rat 
model 
Anoxia primed MSCs improved 
cardiac function through anti-
apoptotic effects and 
attenuation of cardiac 
remodeling 
Hypoxia 
priming 
Hu X et al., 2011 
(140) 
Mouse 
BM MSCs 
Hypoxic gas 
mixture MSC 
priming 
Myocardial infarction rat 
model 
Intravenously injected hypoxia 
primed MSCs showed 
increased homing capacity to 
injured myocardium 
Hypoxia 
priming 
Wei L et al., 2012 
(138) 
Rat BM 
MSCs 
Hypoxic gas 
mixture MSC 
priming 
Transient cerebral ischemia 
rat model 
Intravenously injected hypoxia 
primed MSCs showed 
increased homing to the brain 
and resulted in enhanced 
angiogenesis and 
neurogenesis 
Hypoxia 
priming 
Wei N et al., 2013 
(139) 
Rat BM 
MSCs 
Hypoxic gas 
mixture MSC 
priming 
Focal cortex ischemic stroke 
mouse model 
Intranasal administration of 
hypoxia primed MSCs resulted 
in increased homing and 
neuroprotective effects to the 
ischemic brain region  
Hypoxia 
priming 
Zhang W et al., 
2014 (145) 
Human 
AT MSCs 
Hypoxic gas 
mixture MSC 
priming 
Acute renal 
ischemia/reperfusion injury rat 
model 
Hypoxia primed MSCs 
attenuate renal injury through 
enhanced angiogenic and 
antioxidative capacities 
Hypoxia 
priming 
Overath JM et al., 
2016 (146) 
Mouse AT 
MSCs 
Hypoxic gas 
mixture MSC 
priming 
Cisplatin-induced acute 
kidney injury mouse model 
Hypoxia primed MSCs results 
in improved renal function and 
reduced levels of pro-
inflammatory cytokines 
Hypoxia 
priming  
Liu YY et al., 2017 
(204) 
Rat BM 
MSCs 
Hypoxic gas 
mixture MSC 
priming 
Ischemia-reperfusion lung 
injury rat model 
Hypoxia primed MSCs migrate 
into extravascular lung tissue 
and attenuate I/R lung injury 
through anti-oxidant, anti-
inflammatory and anti-
apoptotic mechanisms 
Hypoxia 
priming  
Kim YH et al., 2018 
(205) 
Human 
UCB 
MSCs 
Hypoxic gas 
mixture MSC 
priming 
Graft-versus-host disease in 
an immune deficiency 
(NOD/SCID) mouse model   
Intravenously injected hypoxia 
primed MSCs resulted in 
significant improved survival, 
less weight loss, and reduced 
histopathologic injuries in 
GVHD target organs 
Table 5. TLRs MSC priming 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRIMING 
METHOD REFERENCE 
TYPE OF 
CELLS TYPE OF PRIMING PRECLINICAL MODEL OUTCOME IN VIVO 
TLRs 
priming 
Yao Y et al., 
2009 (160) 
Mouse BM 
MSCs 
Lipopolysaccharide 
priming 
Myocardial infarction rat 
model 
LPS MSC priming results in 
increased MSC survival post-
transplantation in vivo and as a 
result reduced fibrosis of 
infarcted myocardium, 
neovascularization and recovery 
of the cardiac function 
TLRs 
priming 
Mastri M et al., 
2012 (158) 
Porcine 
BM MSCs 
Polyinosinic-
polycytidylic acid 
priming 
Cardiomyopathy 
hamster model 
Intramuscular injection of 
poly(I:C) primed MSCs resulted 
in cardiac functional 
improvement with a 50% 
reduction in myocardial fibrosis, 
40% reduction in apoptosis and 
55% increase in angiogenesis 
TLRs 
priming 
Waterman RS et 
al., 2012 (206) 
Human BM 
MSCs 
Lipopolysaccharide 
priming 
Epithelial ovarian cancer 
mouse model 
Intraperitoneal injection of LPS 
primed MSCs (MSC1 
phenotype) attenuated tumor 
growth and metastasis 
TLRs 
priming 
Fuenzalida et al., 
2016 (207) 
Human UC 
MSCs 
Polyinosinic-
polycytidylic acid 
priming and  
Lipopolysaccharide 
priming 
Dextran sodium sulfate 
(DSS)- induced 
ulcerative colitis mouse 
model 
- Intraperitoneal injection of 
poly(I:C) primed MSCs 
ameliorated the clinical and 
histopathological severity of the 
disease  
- Intraperitoneal injection of LPS 
primed MSCs significantly 
increased clinical signs of 
disease, colon shortening and 
histological disease index  
TLRs 
priming 
Qui Y et al., 2017 
(208) 
Human UC 
MSCs 
Polyinosinic-
polycytidylic acid 
priming 
Trinitrobenzene sulfonic 
acid-induced colitis 
mouse model 
- Intraperitoneal injection of 
poly(I:C) primed MSCs 
decreased a wide range of 
inflammatory cytokines and 
increased systemic interleukin-
10 (IL-10) levels in colonic 
tissues 
- Poly(I:C) primed MSCs also 
impaired T-helper type 1/17 
(Th1/17) cell expansion and 
enhanced the suppressive 
effects of regulatory T cells 
Table 6. 3D spheroid MSC priming 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRIMING 
METHOD REFERENCE 
TYPE OF 
CELLS 
TYPE OF 
PRIMING PRECLINICAL MODEL OUTCOME IN VIVO 
3D 
spheroid 
priming 
Wang CC et al., 
2009 (189) 
Rat BM 
MSCs 
Spheroid 
MSC 
culturing 
Acute myocardial infarction 
rat model 
Intramyocardial injection of MSC 
spheroids showed superior heart 
function than MSC suspensions by  
increasing vascular density 
3D 
spheroid 
priming 
Bartosh TJ et al., 
2010 (174) 
Human BM 
MSCs 
Spheroid 
MSC 
culturing 
Peritonitis mouse model and 
NOD/SCID mouse model 
- Intraperitoneal injection of MSC 
spheroids was more effective than 
MSCs from adherent monolayer 
cultures in suppressing inflammatory 
responses  
Spheroid MSCs 
- Intravenously injected MSC 
spheroids show better trafficking 
through the lungs and homing to 
spleen, liver, kidney, and heart due to 
their smaller volume from adherent 
cultures 
3D 
spheroid 
priming 
Amos PJ et al., 
2009 (185) 
Human AT 
MSCs 
Spheroid 
MSC 
culturing 
Full-thickness diabetic 
mouse wound model 
Transplantation of MSC spheroids to 
the diabetic wounds resulted in 
significant increase in the rate of 
wound closure compared to wounds 
treated with an equal number of 
MSCs delivered in suspension 
3D 
spheroid 
priming 
Ma D et al., 2011 
(186) 
Rabbit BM 
MSCs 
Spheroid 
MSC 
culturing 
Ectopic bone formation 
nude mouse model and 
Orthotopic bone formation 
mandible rabbit model 
- Subcutaneously injected MSC 
spheroids showed significantly larger 
and denser ectopic bone at the 
injection sites than the MSCs 
suspension group 
- 06&VSKHURLGV¶RUWKRWRSLFLQMHFWLRQ
locally at the mandibular fracture gap 
results in increased bone healing  
3D 
spheroid 
priming 
Bhang SH et al., 
2012 (170) 
Human 
umbilical 
cord blood 
MSCs 
Spheroid 
MSC 
culturing 
Hindlimb ischemia mouse 
model 
Intramuscularly injected MSC 
spheroids showed better survival 
compared to 2D expanded MSCs by 
suppressing apoptotic signaling (Bax 
molecule) and activating anti-
apoptotic signaling (BCL-2 molecule) 
3D 
spheroid 
priming 
Cheng NC et al., 
2012 (173) 
Human AT 
MSCs 
Spheroid 
MSC 
culturing 
Hindlimb ischemia mouse 
model 
Intramuscularly injected MSC 
spheroids showed higher cellular 
retention  
3D 
spheroid 
priming 
Zhang Q et al., 
2012 (175) 
Human 
gingiva 
MSCs 
Spheroid 
MSC 
culturing 
Chemotherapy-induced oral 
mucositis mouse model 
Intraperitoneal injected MSC 
spheroids possessed better 
therapeutic efficacy than their 
adherent cells in reversing body 
weight loss and promoting the 
regeneration of disrupted epithelial 
lining of the mucositic tongues 
3D 
spheroid 
priming 
Suzuki S et al., 
2012 (187) 
- Human 
synovial 
MSCs 
- Rabbit 
synovial 
MSCs 
Spheroid 
MSC 
culturing 
Full-thickness osteochondral 
defect rabbit model 
- Transplantation of MSC spheroids 
at osteochondral defect sites resulted 
in their prompt adherence by surface 
tension, without any loss. 
- MSC spheroid transplantation at 
relatively low density achieved 
successful cartilage regeneration  
3D 
spheroid 
priming 
Suenaga H et al., 
2015 (188) 
 
Human BM 
MSCs 
Spheroid 
MSC 
culturing 
Calvarial bone defect rat 
model 
Locally transplanted MSC spheroids 
resulted in significant bone 
remodeling  
3D 
spheroid 
priming 
Xu Y et al., 2016 
(209) 
Human AT 
MSCs 
Spheroid 
MSC 
culturing 
Ischemia/reperfusion-
induced acute kidney injury 
rat model 
Injection into the kidney cortex of 
MSC spheroids protected the kidney 
against apoptosis, reduced tissue 
damage, promoted vascularization 
and ameliorated renal function  
3D 
spheroid 
priming 
Lee JH et al., 
2016 (210) 
Human AT 
MSCs 
Spheroid 
MSC 
culturing 
Hindlimb ischemia mouse 
model 
Intramuscularly injected MSC 
spheroids showed better proliferation 
than their adherent cells 
Table 7. Advantages and disadvantages of different MSC priming methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PRIMING METHOD ADVANTAGES DISADVANTAGES 
Cytokine and hormonal 
x Increased survival, homing capacity 
and migratory behavior 
x Enhanced anti-inflammatory MSC 
phenotype 
x Use of pro-inflammatory priming 
conditions in vitro that may affect the 
MHC class I and class II levels pre-
implantation in vivo  
Hypoxia x Increased homing capacity, migratory behavior and vascularization 
x Accumulation of reactive oxygen 
species 
x Putative negative effect on MSC 
differentiation capacity 
Immunomodulatory/functional 
x Increased MSC polarization into anti-
inflammatory (MSC-2) phenotype  
x Enhanced production of 
immunoregulatory molecules 
x Increased survival, homing and 
migratory capacities  
x Toll-like receptors (TLRs) activation 
influence MSC differentiation 
capacities in an MSC tissue of origin-
dependent manner 
3D spheroid cultures 
x Increased stability of MSC immuno-
phenotypic profile 
x Enhanced survival, homing, stemness 
features, differentiation potential, 
angiogenic effect and anti-
inflammatory properties 
x Size variability for effective in vivo 
implantation 
x Depending on spheroid size, limited 
diffusion of nutrients and oxygen in 3D 
spheroid core 
x Depending on spheroid size, necrotic 
spheroid core    
  
 
 
 
 
 
